Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.37 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | PAK4 | O96013 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | IGF1R | P08069 | 1/20 | 0.30 |
| ▸ | MET | P08581 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.30 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30586394 | 0.80 | CSNK2A1 (0.41) | CSNK2A1XDHKDM4ECSNK2A2AURKA | |
| SCHEMBL37383 | 0.79 | XDH (0.38) | CSNK2A1XDHKDM4ECSNK2A2AURKA | |
| SCHEMBL29354230 | 0.79 | XDH (0.38) | CSNK2A1XDHKDM4ECSNK2A2AURKA | |
| SCHEMBL1275415 | 0.79 | KDM4E (0.31) | CSNK2A1KDM4ECSNK2A2DYRK1A | |
| SCHEMBL11456966 | 0.78 | XDH (0.37) | CSNK2A1XDHKDM4EAURKADAPK3 | |
| Hydrochloric Acid SCHEMBL4763242 | 0.78 | XDH (0.37) | CSNK2A1XDHKDM4EAURKADAPK3 | |
| SCHEMBL16147073 | 0.76 | CSNK2A1 (0.36) | CSNK2A1CSNK2A2 | |
| SCHEMBL218190 | 0.76 | PARP1 (0.30) | PARP1 | |
| SCHEMBL1371017 | 0.76 | PDPK1 (0.31) | PARP1 | |
| SCHEMBL16146852 | 0.76 | MEN1 (0.36) | CSNK2A1CSNK2A2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112289937-B | Quantum dot light-emitting diode and preparation method thereof | TCL科技集团股份有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-112289937-A | Quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2021-01-29 | — | — | CN | claimed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | claimed |
| CN-112289937-B | Quantum dot light-emitting diode and preparation method thereof | TCL科技集团股份有限公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-112289937-A | Quantum dot light-emitting diode and preparation method thereof | TCL集团股份有限公司 | 2021-01-29 | — | — | CN | disclosed |
| US-9938279-B2 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2018-04-10 | — | — | US | disclosed |
| EP-3050876-A2 | KINASE MODULATORS | Rhizen Pharmaceuticals S.A. (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-5164390-A | Cardiac disorders | ORTHO PHARMACEUTICAL CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| US-5021574-A | Cardiotonic agents, antiarrhythmia agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | CSNK2A1 851/4885XDH 253/4885KDM4E 3951/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | CSNK2A1 67/4885XDH 2930/4885KDM4E 2418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.